Andrew Lo
Andrew Lo's purchase track record
Andrew Lo has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/29/2021 | BBIO | $99K | -26.9% | -37.7% | -20.3% |
| 12/3/2021 | ABCL | $1.22M | -39.2% | -46.2% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
Transaction History
| BBIO | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 | View on chart |
| BBIO | ▼ Sell | Open Market | 24,007 | $1.6M | 11/18/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 30,993 | $2.0M | 11/18/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 36,801 | $2.5M | 11/17/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 3,798 | $255K | 11/17/2025 | View on chart |
| BBIO | ▲ Buy | Grant | 6,589 | $0 | 6/20/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 100,000 | $3.8M | 5/2/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 52,142 | $0 | 9/15/2022 | View on chart |
| BBIO | ▲ Buy | Open Market | 1,500 | $21K | 12/30/2021 | View on chart |
| BBIO | ▲ Buy | Open Market | 6,000 | $77K | 12/29/2021 | View on chart |
| ABCL | ▲ Buy | Open Market | 86,938 | $1.2M | 12/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success
BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.